Shares of several biotech and biopharma names are under pressure on Monday following the resignation of the head of the Food and Drug Administration’s Center for Biologics Evaluation and ...

The resignation of one of the FDA's top officials, Peter Marks, is worrying Wall Street as they await a replacement.

The weekend's resignation announcement of FDA official Peter Marks hit biotech stocks on Monday and sent Wall Street into a frenzy of concern over the future of biopharma approvals in the near term.

Colorado-based Edgewise Therapeutics, a muscle disease-focused biopharma company, closed 23% lower after Wednesday’s trading.

DiaMedica Therapeutics progresses DM199 for ischemic stroke and preeclampsia, aiming to expand treatment windows. Read why ...

Keros Therapeutics is considering whether it needs to find a buyer, while strengthening its stockholder rights as activist ...

Shares in large US and European drugmakers slide, underperforming amid a broad market slump, after President Donald Trump said the US was planning to announce "a major tariff on pharmaceuticals" soon.

Explore Q1 2025's biotech stock moves, from CervoMed's 300% surge to Septerna's struggles. Click for my review of the quarter's winners and losers.

“Participating in the program provides grad students with training and an opportunity to share their research, practice their ...